facebook
twitter
search
search

ImClone CEO, SEC reach agreement

Jan. 20, 2005 at 11:02 AM

WASHINGTON, Jan. 20 (UPI) -- ImClone Chief Executive Samuel Waksal and his father have agreed to pay more than $5 million to settle insider trader charges, court documents say.

The U.S. Securities and Exchange Commission said in federal court papers filed in New York Thursday, Waksal and his father Jack Waksal, without admitting or denying SEC charges, agreed to the disgorgement and civil penalties settlement, subject to court approval.

Sam Waksal earlier paid more than $800,000 in disgorgement and prejudgment interest and was permanently barred from acting as an officer or director of any public company. He currently is serving 87 months in prison in connection with the case.

Martha Stewart also is serving time in connection with the ImClone incident.

The SEC accused Sam Waksal in 2001 of using insider information to sell ImClone stock after learning the U.S. Food and Drug Administration was about to reject the company's cancer treatment drug Erbitux.

Like Us on Facebook for more stories from UPI.com  
Latest Headlines
Top Stories
E-2D aerial refueling capability passes CDR
Norway: New reserves found in North Sea
Shell to tap new Gulf of Mexico oil
Canada awards license for LNG exports to Asia
Greek default leaves bruise on oil markets